NXKK, if you've ever invested in smallcap biotechs that appear to be on the verge of breakthroughs for cancer, you'll become accustomed to very vicious attacks, including some journalists that work for big pharma (undisclosed) who are chemo based while your little biotech is doing leading edge immunotherapy trials for Glioblastoma. The journalist hit pieces are sick, as they also short these stocks too.
Granted, Lightwave has gone through many battles too, that's for sure and hopefully they will win this war on technological advancement in 2022.
Market Data 
Markets 
AI
